Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts

Shiloh M. Martin, Robert T O'Donnell, David L. Kukis, Craig K. Abbey, Hayes McKnight, Julie Sutcliffe, Joseph Tuscano

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalMolecular Imaging and Biology
Volume11
Issue number2
DOIs
StatePublished - 2009

Keywords

  • Cu
  • CD22
  • HB22.7
  • Non-Hodgkin's lymphoma
  • PET

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Imaging and pharmacokinetics of <sup>64</sup>Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts'. Together they form a unique fingerprint.

  • Cite this